Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

Rhea-AI Summary

Nektar (Nasdaq: NKTR) will announce fourth-quarter and year-ended December 31, 2025 financial results on Thursday, March 12, 2026 after U.S. market close. Howard Robin, president and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT.

A live audio-only webcast and the press release will be available on the company’s Investors page. The webcast replay is available through April 12, 2026. Attendees must pre-register to receive dial-in details and a PIN for the live call.

Key Figures

Earnings announcement date: March 12, 2026 Conference call time ET: 5:00 p.m. Eastern Time Conference call time PT: 2:00 p.m. Pacific Time +1 more

4 metrics

Earnings announcement date March 12, 2026 Q4 and full-year 2025 results release after U.S. market close

Conference call time ET 5:00 p.m. Eastern Time Start time for earnings conference call

Conference call time PT 2:00 p.m. Pacific Time Corresponding Pacific Time for the call

Webcast replay end date April 12, 2026 Earnings call webcast replay availability

Market Reality Check

Price: $65.90 Vol: Volume 1,431,065 is below...

normal vol

$65.90 Last Close

Volume Volume 1,431,065 is below the 20-day average of 1,695,380, suggesting no unusual trading ahead of the announcement. normal

Technical Shares at 65.9 are trading above the 200-day MA of 39.79, despite a -6.35% 24h decline and sitting 12.91% below the 52-week high.

Peers on Argus

NKTR fell 6.35% while momentum data show only SANA in the scanner, down 2.79%. O...

1 Down

NKTR fell 6.35% while momentum data show only SANA in the scanner, down 2.79%. Other close peers had mixed moves, indicating today’s decline looks more stock-specific than a broad biotech move.

Historical Context

5 past events · Latest: Feb 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Conference participation	Positive	+2.9%	Announced participation in two March 2026 investor conferences with webcast access.
Feb 17	Research collaboration	Positive	+3.5%	Collaboration with UCSF to study NKTR-0165 in multiple sclerosis models.
Feb 13	Financing closed	Positive	+3.5%	Closed underwritten public offering raising about $460M via shares and pre-funded warrants.
Feb 11	Upsized offering	Positive	+7.0%	Priced upsized $400M public offering to fund Phase 3 rezpegaldesleukin and other uses.
Feb 10	Proposed offering	Positive	+18.5%	Proposed $300M offering under S-3ASR to fund R&D and Phase 3 trials.

Pattern Detected

Recent news, including financings and collaborations, has generally coincided with positive price reactions.

Recent Company History

Over the last few weeks, Nektar has issued several materially relevant updates. In early February, it announced a proposed offering, upsized it, and then closed a deal generating approximately $460 million, all tied to funding Phase 3 development of rezpegaldesleukin. Liquidity disclosures cited about $229.1 million in cash and marketable securities as of Jan 31, 2026. Additional news highlighted positive Phase 2b REZOLVE‑AD data and a multiple sclerosis collaboration around NKTR‑0165. These items, unlike today’s scheduling of an earnings date, tended to elicit positive price reactions.

Market Pulse Summary

This announcement sets the date and time for Nektar’s Q4 and full-year 2025 results, with a conferen...

Analysis

This announcement sets the date and time for Nektar’s Q4 and full-year 2025 results, with a conference call at 5:00 p.m. ET on March 12, 2026 and webcast replay through April 12, 2026. Recent history shows multiple capital raises, liquidity updates, and Phase 2b data releases, all relevant context as investors evaluate upcoming disclosures. Attention will likely focus on how reported results align with the company’s stated development plans and recent financing activity.

Key Terms

earnings call

1 terms

earnings call financial

"To access the conference call, please pre-register at Nektar Earnings Call Registration."

A scheduled public meeting—usually by phone or webcast—where a company’s executives present recent financial results and answer questions from analysts and investors. It matters because listeners hear both the factual “report card” on past performance and the leaders’ tone and outlook for the future; new details or shifts in confidence can change investor expectations and move the stock price, much like a parent-teacher meeting revealing a student’s progress and plans.

AI-generated analysis. Not financial advice.

SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through April 12, 2026.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call. 

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

For Investors:

Vivian Wu
628-895-0661
VWu@nektar.com

Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com 

For Media:

Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2025-on-thursday-march-12-2026-after-close-of-us-based-financial-markets-302698916.html

SOURCE Nektar Therapeutics

FAQ

When will Nektar (NKTR) report Q4 and year-ended 2025 results?

Nektar will report Q4 and year-ended 2025 results on March 12, 2026 after U.S. markets close. According to Nektar, the company will publish a press release and host a conference call that evening to review the financial results.

What time is the Nektar (NKTR) earnings call on March 12, 2026?

The earnings call starts at 5:00 p.m. ET / 2:00 p.m. PT on March 12, 2026. According to Nektar, Howard Robin, president and CEO, will host the audio-only conference call and review the company’s results.

How can investors access the Nektar (NKTR) March 12, 2026 conference call?

Investors can access the call by pre-registering for the Nektar earnings call to receive dial-in details and a PIN. According to Nektar, the press release and live audio webcast link will be posted on the company’s Investors page.

Will Nektar (NKTR) provide a webcast replay of the March 12, 2026 call?

Yes, a webcast replay will be available after the live call and is accessible through April 12, 2026. According to Nektar, the web broadcast replay can be found on the company’s Investors website for later listening.

Who will present Nektar (NKTR) results on the March 12, 2026 call?

Howard Robin, president and CEO, will host and review the results during the conference call. According to Nektar, management will present the fourth-quarter and year-ended 2025 financial results and take questions during the event.